WS Investor
07 Apr 2026, 19:06
Johnson & Johnson announced the European launch of its VARIPULSE Pro platform following CE Mark approval, advancing its pulsed field ablation (PFA) technology for treating cardiac arrhythmias.
The new system features an improved pulse sequence that enables procedures up to five times faster while maintaining precision and safety. It integrates with the CARTO 3 mapping system to support accurate lesion delivery during treatment of conditions such as atrial fibrillation.
The company said the launch reflects ongoing innovation in minimally invasive cardiovascular therapies, with clinical data continuing to be generated through ongoing studies.
VARIPULSE Pro will be showcased at the European Heart Rhythm Association (EHRA) 2026 meeting as part of Johnson & Johnson’s broader push to enhance treatment outcomes in cardiac care.
Business Wire
The new system features an improved pulse sequence that enables procedures up to five times faster while maintaining precision and safety. It integrates with the CARTO 3 mapping system to support accurate lesion delivery during treatment of conditions such as atrial fibrillation.
The company said the launch reflects ongoing innovation in minimally invasive cardiovascular therapies, with clinical data continuing to be generated through ongoing studies.
VARIPULSE Pro will be showcased at the European Heart Rhythm Association (EHRA) 2026 meeting as part of Johnson & Johnson’s broader push to enhance treatment outcomes in cardiac care.
Business Wire